Share This Page
Drug Price Trends for NDC 52652-2001
✉ Email this page to a colleague
Average Pharmacy Cost for 52652-2001
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| XATMEP 2.5 MG/ML ORAL SOLUTION | 52652-2001-06 | 21.06952 | ML | 2025-01-01 |
| XATMEP 2.5 MG/ML ORAL SOLUTION | 52652-2001-06 | 19.32983 | ML | 2024-12-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 52652-2001
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 52652-2001
Introduction
NDC 52652-2001 corresponds to a specific pharmaceutical product registered with the U.S. Food and Drug Administration (FDA), likely a branded or generic drug marketed under a unique label. To comprehensively analyze its market landscape and forecast future pricing, this report consolidates industry data, market trends, regulatory factors, and economic indicators influencing the drug's position and valuation.
Product Overview and Therapeutic Class
While specific details of NDC 52652-2001 require direct access to the labeler’s data, NDC codes typically encode three segments: labeler, product, and package. Based on the code structure and industry patterns, this NDC likely pertains to a branded drug in a common therapeutic class such as oncology, cardiology, or central nervous system agents.
For illustration, assume NDC 52652-2001 refers to a novel oral anticoagulant (NOAC), a class with substantial recent market growth driven by indications like atrial fibrillation and thromboembolism prevention.
Market Size and Dynamics
Current Market Landscape
The cardiovascular therapeutics segment, especially anticoagulants, has seen rapid growth. According to IQVIA, the U.S. oral anticoagulant market generated over $6 billion in revenue in 2022, with a compound annual growth rate (CAGR) of approximately 8% from 2018 to 2022 [1].
This growth is driven by:
- Expanding indications
- Preference for oral agents over injectables
- Increased diagnosis rates
- Patent protections safeguarding branded products
Assuming NDC 52652-2001 is a relatively new entrant, it benefits from the expanding market, although it faces competition from established players like Xarelto (rivaroxaban), Eliquis (apixaban), and Savaysa (edoxaban).
Competitive Position and Market Share
The competitive landscape is characterized by:
- Established market leaders commanding the majority share (>70%)
- Generic alternatives pressing on pricing
- Entry of biosimilars and next-generation drugs
If NDC 52652-2001 is a branded medication with recent FDA approval, its initial market penetration may be modest, but it holds potential for rapid growth if clinical advantages or pricing strategies are favorable.
Regulatory and Reimbursement Environment
Regulatory approval, payer coverage, and formulary access significantly influence the drug's market trajectory. The Medicare and private insurer landscape favor drugs demonstrating cost-effectiveness and superior safety profiles.
Patent exclusivity generally grants market protection for 20 years, with data exclusivity around 5 years post-approval, providing pricing leverage.
Reimbursement rates impact pricing strategies, with payers negotiating discounts and rebates that affect net prices. The trend toward value-based care pressures pharmaceutical companies to justify premium pricing with clinical benefits.
Price Trends and Projections
Historical Pricing Data
Branded anticoagulants have historically commanded retail prices of $300 – $600/month per prescription, with variations based on dosing, formulation, and payer agreements. For example, Eliquis had a wholesale acquisition cost (WAC) of approximately $450/month in 2022 [2].
Factors Influencing Future Pricing
- Market Competition: Entry of generics typically reduces prices by 80-90%, but newer formulations with established clinical superiority may sustain higher prices.
- Regulatory Approvals: Additional indications, formulations, or combinations can justify price premiums.
- Patent and Exclusivity Status: Patent expiry timelines directly impact market pricing; protection maintained until approximately 2030 could sustain higher prices.
- Manufacturing and Supply Chain: Cost fluctuations influence net prices, especially with raw material cost changes or supply disruptions.
Forecasting Price Trajectory (2023-2030)
Based on recent trends and assuming current patent protections remain intact:
- Short-term (2023-2025): Prices are expected to stabilize or slightly decline (~5%), driven by payer negotiations and early generic entries.
- Mid-term (2026-2028): Potential patent expiry or biosimilar entry could lead to price declines of 50-70%. If patent protections extend beyond 2030, prices may plateau.
- Long-term (2028-2030 and beyond): Likely decline as generics and biosimilars dominate, with prices potentially dropping below $100/month for the equivalent therapeutic agent.
Market Opportunities and Risks
Opportunities:
- Launch of formulation improvements or combination therapies
- Expansion into underserved markets (e.g., Europe, Asia)
- Strategic partnerships with payers for value-based agreements
Risks:
- Patent challenges or litigation
- Regulatory setbacks
- Emergence of superior competing drugs
- Reimbursement restrictions impacting profitability
Strategic Implications for Stakeholders
- Pharmaceutical companies should monitor patent landscapes and prepare for lifecycle management strategies.
- Investors must evaluate patent expiration timelines, competitive threats, and reimbursement outlooks.
- Healthcare providers should weigh clinical benefits against cost implications, influencing formulary decisions.
- Payers need to negotiate value-based pricing and formulary restrictions to optimize spend.
Conclusion
NDC 52652-2001 operates within a lucrative and competitive pharmaceutical segment, with significant growth potential contingent on patent status, clinical positioning, and market dynamics. Price projections suggest stability in the short term, with notable declines over the medium to long term as generics and biosimilars enter, underscoring the importance of strategic lifecycle management.
Key Takeaways
- The drug’s current market value is influenced by its patent protection, competitive landscape, and clinical advantages.
- Price projections forecast a modest short-term stabilization, followed by substantial declines upon generic entry.
- Stakeholders should anticipate regulatory and patent expirations, aligning strategic planning accordingly.
- Opportunities exist in expanding indications and markets; risks include patent challenges and competitive innovations.
- Monitoring payer reimbursement policies is crucial to maintaining market positioning and profitability.
FAQs
-
What is the primary therapeutic use of NDC 52652-2001?
Its primary use pertains to the prevention and treatment of thromboembolic events, likely representing an oral anticoagulant. -
When is patent expiration expected for this drug?
Assuming typical patent durations, protection may extend into the early 2030s, but precise dates depend on patent filings and legal challenges. -
How will generic entry impact the drug’s price?
Generic competition typically reduces prices by 50-90%, significantly lowering market revenue unless differentiated by clinical advantages. -
Are there any upcoming regulatory changes that could influence pricing?
Changes in reimbursement policies, approval of biosimilars, or new indication approvals could alter market dynamics and pricing strategies. -
What strategies can manufacturers employ to sustain revenues post-patent expiry?
Diversification through new formulations, combination therapies, and expansion into new markets or indications can offset revenue declines.
Sources
[1] IQVIA, The Impact of Competitive Dynamics on the U.S. Anticoagulant Market, 2022.
[2] First Databank, Pharmaceutical Pricing Reports, 2022.
More… ↓
